Ticker: KANG, Company: iKang Healthcare Group, Inc., Type: 20-F, Date: 2017-08-15, XBRL Interactive Financials
Original SEC Filing: Click here
Webplus: KANG/20170815/20-F/1/000.htm SEC Original: a17-12651_120f.htm
* Not for trading, but only in connection with the listing on The NASDAQ Global Select Market of American depositary shares. Currently, two ADSs represent one Class A common shares. None (Title of Class) None (Title of Class) Indicate the number of outstanding shares of each of the issuers classes of capital or common stock as of the close of
Webplus: KANG/20170815/20-F/2_EX-4.7/000.htm SEC Original: a17-12651_1ex4d7.htm
AGREEMENT EXTENSION NOTICE To: You Notice April 26, 2017 We refer to Cooperation Agreement In accordance with Section 5.2 of the Cooperation Agreement, we hereby elect to extend the Cooperation Agreement for ten (10) years. The new validity period of the Cooperation Agreement therein is from April 27, 2017 to April 26, 2027. ShanghaiMed iKang, Inc. Noted iKang Healthcare Technology
Webplus: KANG/20170815/20-F/3_EX-4.37/000.htm SEC Original: a17-12651_1ex4d37.htm
Cooperation Agreement between iKang Healthcare Group, Inc. and iKang Health Technology Group Co., Ltd. and Ligang Capital Investment (Shenzhen) Co., Ltd. and Yuansheng Investment Management Co., Ltd. of Ningbo Meishan Bonded Port Area and China Industrial Asset Management Limited Contents 1 Definitions and Interpretations 2 2 Way of Cooperation 6 3 Establishment of Merger Fund 7
Webplus: KANG/20170815/20-F/4_EX-4.38/000.htm SEC Original: a17-12651_1ex4d38.htm
Exclusive Business Cooperation Agreement Agreement PRC This Exclusive Business Cooperation Agreement (hereinafter the Party A: Address: Party B: Address: Party Parties Party A and Party B are hereinafter individually referred to as a WHEREAS, 1. 2. 3. NOW, THEREFORE 1. Services Provided by Party A 1.1 1.2 1 1.3 1.3.1 1.3.2 1.4 2. Service Fees and Payment The
Webplus: KANG/20170815/20-F/5_EX-4.39/000.htm SEC Original: a17-12651_1ex4d39.htm
Equity Pledge Agreement Agreement This Equity Pledge Agreement (the Party A: Pledgee Address: Party B: Pledgor ID number: 320102198102151619 Pledgor Party C: Address: the Party the Parties For the purpose of this Agreement, the Pledgee, Pledgor and Party C are individually referred to as Whereas: 1. PRC Main Business 2. Business Cooperation Agreement 3. 1 For the performance of
Webplus: KANG/20170815/20-F/6_EX-4.40/000.htm SEC Original: a17-12651_1ex4d40.htm
Equity Pledge Agreement Agreement This Equity Pledge Agreement (the Party A: Pledgee Address: Party B: Pledgor ID number: 440224198107072865 Pledgor Party C: Address: the Party the Parties For the purpose of this Agreement, the Pledgee, Pledgor and Party C are individually referred to as Whereas: 1. PRC Main Business 2. Business Cooperation Agreement 3. 1 For the performance of
Webplus: KANG/20170815/20-F/7_EX-4.41/000.htm SEC Original: a17-12651_1ex4d41.htm
Exclusive Call Option Agreement THIS EXCLUSIVE OPTION AGREEMENT this Agreement PRC Party A: Party B: Tan Juan, whose ID number is 440224198107072865, with her address at Diwang Mansion, No. 5002, Shennan East Road, Luohu District, Shenzhen, Guangdong Province; ; Party C: Party Parties In this Agreement, Party A, Party B and Party C are referred to as a WHEREAS:
Webplus: KANG/20170815/20-F/8_EX-4.42/000.htm SEC Original: a17-12651_1ex4d42.htm
Power of Attorney I, Hu Haiqing, with ID number of 320102198102151619, being a shareholder of 80% of the equity (My Equity) of Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. is hereby authorized to act on my behalf as my sole exclusive agent and attorney with respect to all matters concerning My Equity, including but not limited to: 1) attending the
Webplus: KANG/20170815/20-F/9_EX-4.43/000.htm SEC Original: a17-12651_1ex4d43.htm
Power of Attorney I, Tan Juan, with ID number of 440224198107072865, being a shareholder of 20% of the equity (My Equity) of Yuanhua Medical Consultancy Services (Shanghai) Co., Ltd. is hereby authorized to act on my behalf as my sole exclusive agent and attorney with respect to all matters concerning My Equity, including but not limited to: 1) attending the
Webplus: KANG/20170815/20-F/10_EX-4.44/000.htm SEC Original: a17-12651_1ex4d44.htm
Supplemental Agreement to the Loan Agreement This Supplemental Agreement to the Loan Agreement (hereinafter referred to as this Supplemental Agreement) is executed on January 17, 2017 by the Parties below in the Peoples Republic of China (hereinafter referred to as PRC) in accordance with applicable PRC laws, regulations, and rules: Borrower: iKang Healthcare Technology Group Co. Ltd. (hereinafter referred to
Webplus: KANG/20170815/20-F/11_EX-4.45/000.htm SEC Original: a17-12651_1ex4d45.htm
Supplemental Agreement II to the Loan Agreement This supplemental agreement to the loan agreement (hereinafter referred to as this Supplemental Agreement) is executed on July 10, 2017 by and between the Parties below in the Peoples Republic of China (hereinafter referred to as PRC) in accordance with applicable PRC laws, regulations, and rules: Borrower: iKang Healthcare Technology Group Co. Ltd.
Webplus: KANG/20170815/20-F/12_EX-4.46/000.htm SEC Original: a17-12651_1ex4d46.htm
Supplemental Agreement II to the Investment Agreement This Supplemental Agreement II to the Investment Agreement (hereinafter referred to as this Supplemental Agreement II) was executed by the following Parties on January 24, 2017 in the Peoples Republic of China (hereinafter referred to as PRC) in accordance with applicable PRC laws, regulations, and rules: Investor: Shenzhen Xingwang Great Health No.1 Investment
Webplus: KANG/20170815/20-F/13_EX-8.1/000.htm SEC Original: a17-12651_1ex8d1.htm
List of Subsidiaries Subsidiaries Place of Incorporation iKang Guobin Healthcare Group, Inc. British Virgin Islands iKang Zhejiang, Inc. British Virgin Islands iKang MRI Center, Inc. British Virgin Islands iKang mHealth, Inc. British Virgin Islands Yuanhua Healthcare Limited Hong Kong MediFast (Hong Kong) Limited Hong Kong
Webplus: KANG/20170815/20-F/14_EX-12.1/000.htm SEC Original: a17-12651_1ex12d1.htm
I, 1. I have reviewed this annual report on Form 20-F of iKang Healthcare Group, Inc. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not
Webplus: KANG/20170815/20-F/15_EX-12.2/000.htm SEC Original: a17-12651_1ex12d2.htm
Certification by the Principal Financial Officer I, Yang Chen, certify that: 1. I have reviewed this annual report on Form 20-F of iKang Healthcare Group, Inc. (the Company); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light
Webplus: KANG/20170815/20-F/16_EX-13.1/000.htm SEC Original: a17-12651_1ex13d1.htm
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.1 16 a17-12651_1ex13d1.htm EX-13.1
Webplus: KANG/20170815/20-F/17_EX-13.2/000.htm SEC Original: a17-12651_1ex13d2.htm
Certification by the Principal Financial Officer (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. EX-13.2 17 a17-12651_1ex13d2.htm EX-13.2
Webplus: KANG/20170815/20-F/18_EX-15.1/000.htm SEC Original: a17-12651_1ex15d1.htm
15 August, 2017 Matter No.:824853 Doc Ref: 103531237 The Directors iKang Healthcare Group, Inc. B-6F Shimao Tower 92A Jianguo Road Chaoyang District Beijing 100022 Peoples Republic of China Dear Sirs, Re: iKang Healthcare Group, Inc. (the Company) Form 20-F). Yours faithfully, Conyers EX-15.1 18 a17-12651_1ex15d1.htm EX-15.1
Webplus: KANG/20170815/20-F/19_EX-15.2/000.htm SEC Original: a17-12651_1ex15d2.htm
August 15, 2017 iKang Healthcare Group, Inc. B-6F Shimao Tower, 92A Jianguo Road Chaoyang District Beijing 100022 Peoples Republic of China Attention: The Board of Directors Dear Sirs, Re: iKang Healthcare Group, Inc. (the Company) Yours faithfully King & Wood Mallesons EX-15.2 19 a17-12651_1ex15d2.htm EX-15.2
Webplus: KANG/20170815/20-F/20_EX-15.3/000.htm SEC Original: a17-12651_1ex15d3.htm
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM We consent to the incorporation by reference in the Registration Statements No. 333-197289 and 333-202544 on Form S-8, of our reports dated August 15, 2017, relating to the consolidated financial statements and financial statement schedule of iKang Healthcare Group, Inc., its subsidiaries, its variable interest entities(VIEs) and VIEs subsidiaries (collectively, the Group), and
Company Info:
Ticker: KANG, Company: iKang Healthcare Group, Inc., Type: 20-F, Date: 2017-08-15, XBRL Interactive FinancialsCIK: 0001524190, Location: F4, SIC: 8011, SIC Desc: SERVICES-OFFICES & CLINICS OF DOCTORS OF MEDICINE
Business Phone & Address:
B-6F, SHIMAO TOWER, 92A JIANGUO ROAD, CHAOYANG DISTRICT
Beijing 100022
-
- Forum
- Topics
- Posts
- Last Post
Leave A Comment
You must be logged in to post a comment.